Calling R-(−)-methamphetamine “inactive” removes qualifications that matter. A 2023 systematic review found limited human data, with effects differing by dose, administration route and the outcome measured. It supports a more specific account than either universal inactivity or equivalence to S-(+)-methamphetamine.
How much human evidence was available?
Barkholtz, Hadzima and Miles searched the literature in October 2022 and included thirteen publications representing ten distinct studies and 99 unique participants. Several publications reused the same participant pools. Counting papers as independent experiments would overstate the evidence base.
The review excluded animal studies and studies of R-methamphetamine formed only as a metabolite of another drug. It synthesized human administration evidence qualitatively because the doses and protocols were too heterogeneous for a meaningful pooled estimate.
What did lower oral doses show?
The review describes an eight-person crossover investigation in which oral R-methamphetamine doses up to 10 mg did not produce significant physiological or subjective differences from placebo on the reported measures. Some sessions also involved a separately identified deuterated intravenous dose for pharmacokinetic analysis.
That result concerns those doses, participants and measures. It does not demonstrate absence of every biological action, exclude uncommon adverse effects or establish safety for unrestricted use. Pharmacokinetic measurements can confirm drug exposure even when a small experiment detects no significant functional effect.
What happened with higher intravenous dosing?
A twelve-person crossover study summarized in the review compared R- and S-methamphetamine at 0.25 and 0.5 mg/kg intravenously, along with placebo and a racemic condition. The lower R dose did not produce significant physiological or subjective effects compared with placebo.
At 0.5 mg/kg, both enantiomers produced similar peak subjective effects, but the R-associated effects dissipated more rapidly, while S-associated cardiovascular and subjective effects lasted longer. Similar peaks do not establish identical time courses or interchangeable overall pharmacology.
These intravenous doses cannot be equated with inhaler administration or a fixed oral dose simply because the same molecule is involved. Route, delivered amount and absorption profile remain part of the result. The racemic condition also should not be treated as a simple arithmetic average of separate-isomer observations.
Were most studies measuring impairment?
No. Much of the literature focused on excretion and drug testing. The review reports urine measurements in nine studies involving 87 participants, with urine as the only matrix in eight studies involving 51 participants. It identified no study quantifying R-methamphetamine in whole blood within the included evidence.
These matrix categories overlap across studies and must not be added as independent participant groups. Urine concentration is not a measurement of subjective effect or task performance, and plasma results do not automatically provide whole-blood concentrations.
Why does the small evidence base matter?
Pharmacodynamic outcomes were assessed in only four studies involving 44 participants. Demographic reporting was incomplete: sex was reported for 66 of the 99 participants and age for 22. The review therefore cannot establish equally precise conclusions across ages, sexes, health conditions or patterns of use.
Historical intranasal studies also differed in formulation, inhalation instructions and dose estimation. A finding from a named historical product should not be assumed to describe every current product with similar branding. This review is a record of evidence through its search date, not a current product directory.
What is the defensible interpretation?
R-methamphetamine generally showed less or shorter activity in the reviewed comparisons, with important dose- and route-specific exceptions. The evidence does not justify a universal “no effects” label or a universal potency conversion between isomers.
For an individual toxicology interpretation, identify the enantiomer, specimen and exposure evidence separately from the proposed effect. Neither detection of R-methamphetamine nor the absence of a significant effect in one small study determines a person’s impairment at another time.
Source
Barkholtz HM, Hadzima R, Miles A. Pharmacology of R-(−)-Methamphetamine in Humans: A Systematic Review of the Literature. ACS Pharmacology & Translational Science. 2023;6:914–924. doi:10.1021/acsptsci.3c00019. Historical systematic review; individual experiments are summarized as review evidence.
Leave a Reply